stocks logo

KTTA Valuation

Pasithea Therapeutics Corp
$
0.977
+0.036(+3.820%)
  • Overview
  • Forecast
  • Valuation

KTTA Relative Valuation

KTTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KTTA is overvalued; if below, it's undervalued.

Historical Valuation

No Data

Competitors Valuation Multiple

The average P/S ratio for KTTA's competitors is 0.30, providing a benchmark for relative valuation. Pasithea Therapeutics Corp Corp (KTTA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

FAQ

arrow icon

Is Pasithea Therapeutics Corp (KTTA) currently overvalued or undervalued?

Pasithea Therapeutics Corp (KTTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 12.18. The fair price of Pasithea Therapeutics Corp (KTTA) is between NaN to NaN according to relative valuation methord.
arrow icon

What is Pasithea Therapeutics Corp (KTTA) fair value?

arrow icon

How does KTTA's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?

arrow icon

What is the current FCF Yield for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?

arrow icon

What is the current Forward P/E ratio for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?

arrow icon

What is the current Forward P/S ratio for Pasithea Therapeutics Corp (KTTA) as of May 20 2025?